Stay updated on Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.

Latest updates to the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page
- Check2 days agoChange DetectedAdded a link to the Genetic and Rare Diseases Information Center resources for squamous cell carcinoma of the head and neck, and a related topic entry for head and neck squamous cell carcinoma.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed.SummaryDifference0.1%

- Check24 days agoChange DetectedThe page revision label was updated from v3.4.2 to v3.4.3 in the header.SummaryDifference0.1%

- Check52 days agoChange DetectedAdded Revision: v3.4.2. Removed the government funding lapse notice and the v3.4.1 revision entry.SummaryDifference0.5%

- Check60 days agoChange DetectedNotice about a lapse in government funding and NIH Clinical Center operating status was added to the site; link to opm.gov for updates. The site revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check67 days agoChange DetectedAdded and updated administrative metadata on the study page: No FEAR Act Data, Last Update Submitted that Met QC Criteria, Last Update Posted, and Revision: v3.4.0. Removed the older labels Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.3%

Stay in the know with updates to Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.